INTRODUCTION
Hair loss disorders or alopecia cause significant impacts on patients' quality of life, reduce self-esteem, and increase stress.1 To some extent, this is a natural phenomenon that results in the shedding of up to 80 to 100 telogen hairs per day in a healthy adult.2 Nonetheless, a severe increase in this number or the loss of anagen hairs are pathological signs.3
Alopecia can be categorized as cicatricial and non-cicatricial, with female androgenetic alopecia (AGA) and female pattern hair loss (FPHL) included in the latter category.4 Their incidence rises with age and is closely related to the emergence of menopause.5,6 The imbalance between androgens and estrogens that occurs during this stage affects the proliferative capacity of the dermal papilla itself, and also greatly impairs the vascular microenvironment of the follicle, leading to overall decreased density, thickness, and altered texture.6,7
With hair as a key aesthetic-defining feature, FPHL has a noticeable psychological burden. Different non-cosmetic approaches are available to reduce its impact, such as drug administration, aesthetic camouflage techniques, or, most recently, hair transplantation.8
Nonetheless, side effects, invasiveness, lack of universality, and incomplete hair restoration capacity of these interventions require the development of novel treatments for AGA patients. In this regard, extensive efforts in the cosmetic industry have led to a range of treatments claiming anti-hair loss, hair growth, and scalp rejuvenation properties, with topical serums meeting an important part of these requirements.9
Some patented ingredients have shown efficacy in this field, such as Redensyl, Capixyl, Procapil, or Anagain, resulting in even more beneficial results than the benchmark minoxidil in some contexts.10-12 Thus, the inclusion of such ingredients, together with botanical extracts, antioxidants, and anti-inflammatory molecules for which evidence exists that supports a healthy scalp, can be proposed as a rationale for new formulations to treat AGA.13-16 For this reason, this prospective clinical trial aimed at evaluating the clinical effectiveness of the combined application of a two-step cosmetic serum system developed by KilgourMD at reducing female hair loss in a predominantly menopausal-aged cohort.
Alopecia can be categorized as cicatricial and non-cicatricial, with female androgenetic alopecia (AGA) and female pattern hair loss (FPHL) included in the latter category.4 Their incidence rises with age and is closely related to the emergence of menopause.5,6 The imbalance between androgens and estrogens that occurs during this stage affects the proliferative capacity of the dermal papilla itself, and also greatly impairs the vascular microenvironment of the follicle, leading to overall decreased density, thickness, and altered texture.6,7
With hair as a key aesthetic-defining feature, FPHL has a noticeable psychological burden. Different non-cosmetic approaches are available to reduce its impact, such as drug administration, aesthetic camouflage techniques, or, most recently, hair transplantation.8
Nonetheless, side effects, invasiveness, lack of universality, and incomplete hair restoration capacity of these interventions require the development of novel treatments for AGA patients. In this regard, extensive efforts in the cosmetic industry have led to a range of treatments claiming anti-hair loss, hair growth, and scalp rejuvenation properties, with topical serums meeting an important part of these requirements.9
Some patented ingredients have shown efficacy in this field, such as Redensyl, Capixyl, Procapil, or Anagain, resulting in even more beneficial results than the benchmark minoxidil in some contexts.10-12 Thus, the inclusion of such ingredients, together with botanical extracts, antioxidants, and anti-inflammatory molecules for which evidence exists that supports a healthy scalp, can be proposed as a rationale for new formulations to treat AGA.13-16 For this reason, this prospective clinical trial aimed at evaluating the clinical effectiveness of the combined application of a two-step cosmetic serum system developed by KilgourMD at reducing female hair loss in a predominantly menopausal-aged cohort.
